Recursion Pharmaceuticals Long Term Debt

Recursion Pharmaceuticals (RXRX) currently reports a long-term debt of $39M as of June 2026. That compares with $68M in the prior-year period — down 42.0% year over year. Use the charts on this page to explore Recursion Pharmaceuticals's long-term debt history and peer comparisons.

Recursion Pharmaceuticals's long-term debt decreased from $68M to $39M — a 42.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Recursion Pharmaceuticals reported $39M in long-term debt as of June 2026. That compares with $68M in the prior-year period — down 42.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $39M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Recursion Pharmaceuticals, and consider following RXRX for alerts when major investors trade the stock.

Recursion Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $39M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RXRX with unrelated industries.